Mediera Corporation (TPEX:5398)
Taiwan · Delayed Price · Currency is TWD 14.50
+0.05 (0.35%)
Jul 30, 2026, 1:30 PM CST
Mediera Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 233.15 | 229.85 | 238.48 | 192.9 | 257.55 | 351.56 |
Revenue Growth | 3.40% | -3.62% | 23.63% | -25.10% | -26.74% | -4.44% |
Gross Profit Gross Profit Growth | 87.13 | 85.25 | 84.48 | 33.46 | 65.76 | 117.56 |
Operating Income Operating Income Growth | 13.4 | 11.92 | 4.02 | -41.06 | -12.53 | 23.8 |
Net Income Net Income Growth | 16.15 | 17.36 | 8.75 | -31.81 | -6.79 | 16.21 |
Earnings Per Share EPS Growth | 0.33 | 0.35 | 0.18 | -0.64 | -0.14 | 0.33 |
EPS Growth | - | 97.84% | - | - | - | -2.68% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Physical Examination Physical Examination Growth | 133.98 | 129.88 | 134.57 | 19.33 | 49.47 | - |
Pharmaceutical Biotechnology Pharmaceutical Biotechnology Growth | 99.18 | 99.97 | 103.92 | 173.56 | 208.08 | 351.56 |
Total Total Growth | 233.15 | 229.85 | 238.48 | 192.9 | 257.55 | 351.56 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 145.48 | 111.61 | 113.39 | 130.59 | 104.39 | 132.01 |
Total Debt Total Debt Growth | 10.02 | 12.6 | 30.3 | 11.61 | 21.05 | 21.8 |
Net Cash (Debt) Net Cash Growth | 135.46 | 99.01 | 83.1 | 118.98 | 83.34 | 110.21 |
Net Cash Growth | 32.69% | 19.15% | -30.16% | 42.77% | -24.38% | -9.57% |
Net Cash Per Share Net Cash Per Share Growth | 2.74 | 2.00 | 1.68 | 2.41 | 1.68 | 2.22 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 31.78 | 9.14 | -23.58 | 30.62 | -22.4 | 103.15 |
Capital Expenditures CapEx Growth | -1.44 | -1.73 | -0.31 | -0.49 | -15.82 | -2.22 |
Free Cash Flow Free Cash Flow Growth | 30.34 | 7.41 | -23.89 | 30.14 | -38.22 | 100.93 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 37.37% | 37.09% | 35.43% | 17.35% | 25.53% | 33.44% |
Operating Margin | 5.75% | 5.18% | 1.69% | -21.29% | -4.86% | 6.77% |
Pretax Margin | 10.68% | 10.37% | 5.76% | -15.91% | -1.88% | 5.89% |
Profit Margin | 6.93% | 7.55% | 3.67% | -16.49% | -2.64% | 4.61% |
FCF Margin | 13.01% | 3.22% | -10.02% | 15.62% | -14.84% | 28.71% |
| Fiscal Year | FY 2021 |
|---|---|
| Period Ending | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.140 |
Dividend Per Share Growth | -44.00% |
Dividend Yield | 0.70% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 44.26 | 74.10 | 109.94 | - | - | 61.78 |
P/FCF Ratio | 23.56 | 173.59 | - | 25.03 | - | 9.92 |
PS Ratio | 3.07 | 5.60 | 4.03 | 3.91 | 3.15 | 2.85 |